1. Home
  2. KROS vs LYTS Comparison

KROS vs LYTS Comparison

Compare KROS & LYTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KROS
  • LYTS
  • Stock Information
  • Founded
  • KROS 2015
  • LYTS 1976
  • Country
  • KROS United States
  • LYTS United States
  • Employees
  • KROS N/A
  • LYTS N/A
  • Industry
  • KROS Biotechnology: Pharmaceutical Preparations
  • LYTS Building Products
  • Sector
  • KROS Health Care
  • LYTS Consumer Discretionary
  • Exchange
  • KROS Nasdaq
  • LYTS Nasdaq
  • Market Cap
  • KROS 558.9M
  • LYTS 518.5M
  • IPO Year
  • KROS 2020
  • LYTS N/A
  • Fundamental
  • Price
  • KROS $13.45
  • LYTS $17.85
  • Analyst Decision
  • KROS Buy
  • LYTS Strong Buy
  • Analyst Count
  • KROS 13
  • LYTS 2
  • Target Price
  • KROS $20.63
  • LYTS $26.00
  • AVG Volume (30 Days)
  • KROS 603.2K
  • LYTS 105.7K
  • Earning Date
  • KROS 08-06-2025
  • LYTS 08-14-2025
  • Dividend Yield
  • KROS N/A
  • LYTS 1.12%
  • EPS Growth
  • KROS N/A
  • LYTS N/A
  • EPS
  • KROS 0.11
  • LYTS 0.72
  • Revenue
  • KROS $214,713,000.00
  • LYTS $547,316,000.00
  • Revenue This Year
  • KROS $5,006.76
  • LYTS $21.02
  • Revenue Next Year
  • KROS N/A
  • LYTS $7.32
  • P/E Ratio
  • KROS $123.44
  • LYTS $24.79
  • Revenue Growth
  • KROS 91657.70
  • LYTS 17.89
  • 52 Week Low
  • KROS $9.12
  • LYTS $13.63
  • 52 Week High
  • KROS $72.37
  • LYTS $25.50
  • Technical
  • Relative Strength Index (RSI)
  • KROS 43.42
  • LYTS 68.63
  • Support Level
  • KROS $13.24
  • LYTS $16.92
  • Resistance Level
  • KROS $13.77
  • LYTS $17.35
  • Average True Range (ATR)
  • KROS 0.38
  • LYTS 0.36
  • MACD
  • KROS -0.04
  • LYTS 0.11
  • Stochastic Oscillator
  • KROS 28.00
  • LYTS 100.00

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

About LYTS LSI Industries Inc.

LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Lighting segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays and custom display elements.

Share on Social Networks: